Mineralocorticoid Receptor

盐皮质激素受体 (MR) 是一种细胞内类固醇激素受体,是核受体超家族的成员,可介导两种重要的肾上腺类固醇(醛固酮和皮质醇)的生理作用。盐皮质激素受体与糖皮质激素受体 (GR) 密切相关,可以无差别地结合盐皮质激素和糖皮质激素。远端肾单位中的盐皮质激素受体被其配体醛固酮激活,在钠重吸收和血压调节中起重要作用。除了调节钠平衡和控制血压外,醛固酮-人盐皮质激素受体串联还对心血管和中枢神经系统发挥重要的调节作用。

盐皮质激素受体参与调节钠转运致密上皮细胞(如远端肾单位、结肠、肺、唾液腺和汗腺)的水电解稳态。在这些上皮靶细胞中,醛固酮作用的盐皮质激素特异性是由酶 11β-羟基类固醇脱氢酶 2 (11-HSD2) 赋予的,该酶将活性糖皮质激素转化为无活性代谢物。盐皮质激素受体也在非上皮组织中表达,例如心脏、脑的某些区域、大血管和单核白细胞。配体激活的盐皮质激素受体在细胞核内转位,与一致的糖皮质激素反应元件 (GRE) 序列相互作用后,发挥转录因子的作用。盐皮质激素受体可以激活或抑制靶基因的转录,而靶基因的鉴定正在受到深入研究。

Mineralocorticoid receptor (MR) is an intracellular steroid hormone receptor, and a member of the nuclear receptor superfamily, that mediates the physiological action of two important adrenal steroids, aldosterone and cortisol. Mineralocorticoid receptor is closely related to the glucocorticoid receptor (GR), and it can indifferently bind mineralocorticoid and glucocorticoid hormones. Activation of the mineralocorticoid receptor in the distal nephron by its ligand, aldosterone, plays an important role in sodium reabsorption and blood pressure regulation. Besides the regulation of sodium balance and the control of blood pressure, aldosterone-human mineralocorticoid receptor tandem also exerts important regulatory functions on the cardiovascular and central nervous systems.

Mineralocorticoid receptor participates in the regulation of hydroelectrolytic homeostasis in sodium-transporting tight epithelia such as distal nephron, colon, lung, and salivary and sweat glands. In such epithelial target cells, the mineralocorticoid specificity of aldosterone action is given by the enzyme 11β-hydroxysteroid dehydrogenase 2 (11-HSD2), which converts active glucocorticoids into inactive metabolites. Mineralocorticoid receptor is also expressed in nonepithelial tissues such as the heart, some areas of the brain, large blood vessels, and mononuclear leukocytes. The ligand-activated mineralocorticoid receptor is translocated in the nucleus and acts as a transcription factor after its interaction with the consensus glucocorticoid response element (GRE) sequences. Mineralocorticoid receptor could activate or inhibit transcription of target genes whose identification is under intense investigation.

共 65种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
(R)-Finerenone
(R)-BAY 94-8862

(R)-Finerenone ((R)-BAY 94-8862) 是 Finerenone (MS-J20782) 的 R-异构体,而 Finerenone 是第三代选择性、具有口服活性的非甾体类盐皮质激素受体 (MR) 拮抗剂 (IC50 = 18 nM),与糖皮质激素受体 (GR)、雄激素受体 (AR) 和孕酮受体 (AR) 相比表现出良好的选择性 (> 500-fold),在心肾疾病如 2 型糖尿病和慢性肾脏疾病的研究中具有潜在的应用前景。

1050477-30-9
Antagonist
99.70%
(R)-Finerenone
(Rac)-Finerenone
(Rac)-BAY 94-8862

(Rac)-Finerenone ((Rac)-BAY 94-8862) 是 Finerenone 的外消旋体,而 Finerenone (BAY 94-8862) 是一种第三代选择性、口服活性的非甾体类盐皮质激素受体 (MR) 拮抗剂 (IC50=18 nM),对糖皮质激素受体 (GR)、雄激素受体 (AR) 和孕酮受体 (AR) 表现出良好的选择性 (>500-fold)。

1050477-27-4
Antagonist
99.66%
(Rac)-Finerenone
(Rac)-Finerenone-d5
(Rac)-BAY 94-8862-d5

(Rac)-Finerenone-d5((Rac)-BAY 94-8862-d5)是氘代标记的 (Rac)-Finerenone(MS-P26935),而 (Rac)-Finerenone((Rac)-BAY 94-8862)是 Finerenone 的外消旋体;Finerenone(BAY 94-8862)是第三代选择性、具有口服活性的非甾体类盐皮质激素受体(MR)拮抗剂(IC50=18 nM),与糖皮质激素受体(GR)、雄激素受体(AR)和孕酮受体(AR)相比表现出良好的选择性(>500-fold)。

2917530-31-3
(Rac)-Finerenone-d5
(S)-Baxdrostat
(S)-CIN-107

(S)-Baxdrostat 是醛固酮合酶 (aldosterone synthase) 抑制剂 Baxdrostat 的 S-对映异构体。

1428652-16-7
Inhibitor
98.84%
(S)-Baxdrostat
18-Oxocortisol

18-Oxocortisol 是一种由醛固酮合酶 (CYP11B2) 产生的皮质醇衍生物,是天然存在的盐皮质激素 (mineralocorticoid) 激动剂,也是肾上腺静脉采样中的生物标志物。

2410-60-8
Antagonist
98.47%
18-Oxocortisol
18-Hydroxy-11-deoxy corticosterone
18-羟基-11-脱氧皮质酮; 18-OH-DOC; 11-Deoxy-18-hydroxycorticosterone

18-Hydroxy-11-deoxy corticosterone (18-OH-DOC) 是一种合成受促肾上腺皮质激素 (ACTH) 和血管紧张素 II 调节的盐皮质激素,作为孕酮代谢的中间产物在调节血压和水盐平衡中发挥重要作用,持续输注可提高大鼠的收缩压,且在 db/db 型 2 型糖尿病小鼠模型中其血浆水平显著升高,提示其可能参与代谢紊乱和糖尿病相关的调控,有望用于高血压、糖尿病等领域的研究。

379-68-0
Ligand
18-羟基-11-脱氧皮质酮
21-Hydroxyeplerenone
21-羟基普利酮

21-Hydroxyeplerenone 是盐皮质激素受体拮抗剂 Eplerenone (MS-X36449) 的主要代谢产物,由依普利酮经细胞色素 P450 (CYP) 同工酶 CYP3A4 代谢形成。

334678-67-0
Control
21-羟基普利酮
ACTH (6-24) (human)
Adrenocorticotropic hormone (6-24)

ACTH (6-24) (human)(Adrenocorticotropic hormone (6-24))是 ACTH 片段,作为 ACTH (1-39) 和 ACTH (5-24) 诱导的类固醇生成的竞争性抑制剂(Kd 分别为 13.4 和 3.4 nM),并可抑制 hPTH 1-34 诱导的皮质酮产生和 cAMP 积累。

33512-65-1
Inhibitor
ACTH (6-24) (human)
Apararenone
MT-3995

Apararenone (MT-3995) 是一种新型非甾体类盐皮质激素受体 (mineralocorticoid receptor) 拮抗剂,目前正在开发用于糖尿病性肾病和非酒精性脂肪性肝炎的研究。

945966-46-1
Antagonist
98.06%
Apararenone
Apararenone (Standard)
MT-3995 (Standard)

Apararenone (Standard) 是 Apararenone (MS-L02974) 的分析标准品,本产品用于研究及分析应用,而 Apararenone (MT-3995) 是一种新型非甾体类盐皮质激素受体 (mineralocorticoid receptor) 拮抗剂,正在开发用于研究糖尿病性肾病和非酒精性脂肪性肝炎。

945966-46-1
Antagonist
Apararenone (Standard)
Balcinrenone
AZD9977

Balcinrenone (AZD9977) 是一种有效的、选择性的、具有口服活性的盐皮质激素受体 (MR) 调节剂,用于心力衰竭和慢性肾病的研究。

1850385-64-6
Modulator
99.62%
Balcinrenone
Baxdrostat
CIN-107

Baxdrostat是一种醛固酮合成酶抑制剂。

1428652-17-8
Inhibitor
99.32%
Baxdrostat

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础